~~<i id='863EA2D19B'><strike id='863EA2D19B'><tt id='863EA2D19B'><pre id='863EA2D19B'></pre></tt></strike></i>~~

Home» knowledge» leisure time

leisure time

author：explore 2025-09-30 13:05:40 Page View：7986

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: Medically tailored meals may get standardized
Next article： Supreme Court strikes down use of affirmative action

comprehensive

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

Primary care physicians play key roles in Alzheimer's management

AdobeWhentheresultsofPresidentBiden’sannualphysicalwerereleasedlastmonth,manywonderedwhyhisprimaryca

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Abortion pill case raises question: who can sue the FDA?

AdobeWASHINGTON—SupremeCourtJusticeSamuelAlitohadaclearquestionatTuesday’sargumentsovertheabortionpi